vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and Spire Global, Inc. (SPIR). Click either name above to swap in a different company.
Journey Medical Corp is the larger business by last-quarter revenue ($16.1M vs $15.8M, roughly 1.0× Spire Global, Inc.). Journey Medical Corp runs the higher net margin — -7.8% vs -176.6%, a 168.9% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs -26.9%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs -32.6%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
Spire Global, Inc. is a space-to-cloud data and analytics company that specializes in the tracking of global data sets powered by a large constellation of nanosatellites, such as the tracking of maritime, aviation and weather patterns.
DERM vs SPIR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $15.8M |
| Net Profit | $-1.2M | $-28.0M |
| Gross Margin | — | 40.2% |
| Operating Margin | -2.8% | -164.1% |
| Net Margin | -7.8% | -176.6% |
| Revenue YoY | 27.3% | -26.9% |
| Net Profit YoY | -182.0% | 42.7% |
| EPS (diluted) | $-0.04 | $-0.85 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $15.8M | ||
| Q3 25 | $17.0M | $12.7M | ||
| Q2 25 | $15.0M | $19.2M | ||
| Q1 25 | $13.1M | $23.9M | ||
| Q4 24 | $12.6M | $21.7M | ||
| Q3 24 | $14.6M | $28.6M | ||
| Q2 24 | $14.9M | $25.4M | ||
| Q1 24 | $13.0M | $34.8M |
| Q4 25 | $-1.2M | $-28.0M | ||
| Q3 25 | $-2.3M | $-19.7M | ||
| Q2 25 | $-3.8M | $119.6M | ||
| Q1 25 | $-4.1M | $-20.7M | ||
| Q4 24 | $1.5M | $-48.8M | ||
| Q3 24 | $-2.4M | $-12.5M | ||
| Q2 24 | $-3.4M | $-16.6M | ||
| Q1 24 | $-10.4M | $-25.5M |
| Q4 25 | — | 40.2% | ||
| Q3 25 | — | 36.6% | ||
| Q2 25 | — | 48.9% | ||
| Q1 25 | — | 36.8% | ||
| Q4 24 | 82.3% | 32.4% | ||
| Q3 24 | 63.9% | 44.5% | ||
| Q2 24 | 56.0% | 43.0% | ||
| Q1 24 | 47.7% | 26.5% |
| Q4 25 | -2.8% | -164.1% | ||
| Q3 25 | -9.0% | -166.1% | ||
| Q2 25 | -19.2% | -122.7% | ||
| Q1 25 | -25.3% | -106.5% | ||
| Q4 24 | 17.7% | -144.1% | ||
| Q3 24 | -19.8% | -48.0% | ||
| Q2 24 | -19.7% | -48.6% | ||
| Q1 24 | -77.4% | -34.4% |
| Q4 25 | -7.8% | -176.6% | ||
| Q3 25 | -13.6% | -155.3% | ||
| Q2 25 | -25.3% | 623.4% | ||
| Q1 25 | -31.0% | -86.5% | ||
| Q4 24 | 12.1% | -225.2% | ||
| Q3 24 | -16.3% | -43.7% | ||
| Q2 24 | -22.6% | -65.2% | ||
| Q1 24 | -80.1% | -73.3% |
| Q4 25 | $-0.04 | $-0.85 | ||
| Q3 25 | $-0.09 | $-0.61 | ||
| Q2 25 | $-0.16 | $3.72 | ||
| Q1 25 | $-0.18 | $-0.77 | ||
| Q4 24 | $0.10 | $-1.93 | ||
| Q3 24 | $-0.12 | $-0.50 | ||
| Q2 24 | $-0.17 | $-0.68 | ||
| Q1 24 | $-0.53 | $-1.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $81.8M |
| Total DebtLower is stronger | $25.3M | — |
| Stockholders' EquityBook value | $31.9M | $112.9M |
| Total Assets | $94.6M | $211.0M |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $81.8M | ||
| Q3 25 | $24.9M | $96.8M | ||
| Q2 25 | $20.3M | $117.6M | ||
| Q1 25 | $21.1M | $35.9M | ||
| Q4 24 | $20.3M | $19.2M | ||
| Q3 24 | $22.5M | $36.6M | ||
| Q2 24 | $23.9M | $45.8M | ||
| Q1 24 | $24.1M | $63.7M |
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | $103.7M | ||
| Q4 24 | $24.9M | $103.1M | ||
| Q3 24 | $19.8M | $4.9M | ||
| Q2 24 | $19.7M | $4.9M | ||
| Q1 24 | $14.7M | $123.1M |
| Q4 25 | $31.9M | $112.9M | ||
| Q3 25 | $25.9M | $133.1M | ||
| Q2 25 | $19.2M | $149.2M | ||
| Q1 25 | $21.5M | $3.7M | ||
| Q4 24 | $20.1M | $-11.7M | ||
| Q3 24 | $10.9M | $30.8M | ||
| Q2 24 | $11.3M | $40.3M | ||
| Q1 24 | $13.0M | $52.5M |
| Q4 25 | $94.6M | $211.0M | ||
| Q3 25 | $85.2M | $224.3M | ||
| Q2 25 | $81.2M | $239.5M | ||
| Q1 25 | $85.0M | $208.8M | ||
| Q4 24 | $80.2M | $193.6M | ||
| Q3 24 | $64.0M | $224.2M | ||
| Q2 24 | $65.2M | $230.8M | ||
| Q1 24 | $66.6M | $252.3M |
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | 27.92× | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | 0.16× | ||
| Q2 24 | 1.75× | 0.12× | ||
| Q1 24 | 1.13× | 2.35× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $-4.3M |
| Free Cash FlowOCF − Capex | — | $-16.2M |
| FCF MarginFCF / Revenue | — | -102.1% |
| Capex IntensityCapex / Revenue | — | 75.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-92.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $-4.3M | ||
| Q3 25 | $-2.4M | $-12.0M | ||
| Q2 25 | $-942.0K | $-35.1M | ||
| Q1 25 | $-2.8M | $-8.4M | ||
| Q4 24 | $2.2M | $-19.2M | ||
| Q3 24 | $-1.2M | $14.0M | ||
| Q2 24 | $-5.2M | $-4.4M | ||
| Q1 24 | $-5.0M | $-8.8M |
| Q4 25 | — | $-16.2M | ||
| Q3 25 | — | $-20.4M | ||
| Q2 25 | — | $-38.7M | ||
| Q1 25 | — | $-17.3M | ||
| Q4 24 | — | $-24.3M | ||
| Q3 24 | — | $5.1M | ||
| Q2 24 | — | $-9.9M | ||
| Q1 24 | — | $-15.9M |
| Q4 25 | — | -102.1% | ||
| Q3 25 | — | -161.3% | ||
| Q2 25 | — | -201.7% | ||
| Q1 25 | — | -72.6% | ||
| Q4 24 | — | -112.2% | ||
| Q3 24 | — | 17.8% | ||
| Q2 24 | — | -39.0% | ||
| Q1 24 | — | -45.7% |
| Q4 25 | — | 75.1% | ||
| Q3 25 | — | 66.2% | ||
| Q2 25 | — | 18.8% | ||
| Q1 25 | — | 37.3% | ||
| Q4 24 | — | 23.5% | ||
| Q3 24 | — | 31.2% | ||
| Q2 24 | — | 21.8% | ||
| Q1 24 | — | 20.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.29× | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
SPIR
Segment breakdown not available.
